Teacher Retirement System of Texas Acquires 5,594 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Teacher Retirement System of Texas increased its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 17.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 37,516 shares of the biopharmaceutical company’s stock after purchasing an additional 5,594 shares during the quarter. Teacher Retirement System of Texas’ holdings in Halozyme Therapeutics were worth $1,794,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Heck Capital Advisors LLC bought a new position in shares of Halozyme Therapeutics in the fourth quarter worth about $29,000. CBIZ Investment Advisory Services LLC bought a new stake in Halozyme Therapeutics during the 4th quarter worth approximately $29,000. Smartleaf Asset Management LLC lifted its holdings in Halozyme Therapeutics by 29.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 197 shares in the last quarter. Venturi Wealth Management LLC bought a new position in shares of Halozyme Therapeutics in the fourth quarter worth approximately $69,000. Finally, Parkside Financial Bank & Trust increased its stake in shares of Halozyme Therapeutics by 21.8% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company’s stock worth $86,000 after purchasing an additional 322 shares in the last quarter. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director Jeffrey William Henderson sold 5,000 shares of the firm’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $58.69, for a total value of $293,450.00. Following the completion of the sale, the director now directly owns 33,611 shares in the company, valued at $1,972,629.59. This trade represents a 12.95 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $58.05, for a total transaction of $580,500.00. Following the transaction, the senior vice president now directly owns 185,453 shares of the company’s stock, valued at $10,765,546.65. The trade was a 5.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 31,697 shares of company stock worth $1,754,451. Corporate insiders own 2.40% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently weighed in on HALO shares. Benchmark reaffirmed a “buy” rating and issued a $75.00 target price on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Wells Fargo & Company cut their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. HC Wainwright reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Thursday, March 6th. Finally, Piper Sandler increased their price objective on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a report on Friday, January 10th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, Halozyme Therapeutics has an average rating of “Moderate Buy” and an average price target of $62.78.

Halozyme Therapeutics Stock Up 1.0 %

Shares of HALO opened at $64.48 on Friday. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. The stock has a market capitalization of $7.97 billion, a price-to-earnings ratio of 18.80, a price-to-earnings-growth ratio of 0.42 and a beta of 1.32. Halozyme Therapeutics, Inc. has a 1 year low of $37.73 and a 1 year high of $66.00. The business’s 50 day simple moving average is $58.98 and its 200-day simple moving average is $54.85.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, beating the consensus estimate of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The business had revenue of $298.01 million during the quarter, compared to analyst estimates of $285.74 million. As a group, equities analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.